Compare GOTU & LYEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GOTU | LYEL |
|---|---|---|
| Founded | 2014 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 345.8M | 320.1M |
| IPO Year | 2019 | 2021 |
| Metric | GOTU | LYEL |
|---|---|---|
| Price | $1.69 | $11.85 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $30.60 |
| AVG Volume (30 Days) | ★ 717.2K | 132.9K |
| Earning Date | 05-15-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $36,000.00 |
| Revenue This Year | $17.33 | N/A |
| Revenue Next Year | $13.02 | $8,712.13 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.40 | $8.49 |
| 52 Week High | $4.12 | $45.00 |
| Indicator | GOTU | LYEL |
|---|---|---|
| Relative Strength Index (RSI) | 49.80 | 30.53 |
| Support Level | $1.65 | N/A |
| Resistance Level | $2.01 | $13.88 |
| Average True Range (ATR) | 0.10 | 1.25 |
| MACD | 0.02 | 0.07 |
| Stochastic Oscillator | 58.95 | 4.56 |
Gaotu Techedu Inc is a technology-driven education company that provides online live courses in a large-class setting backed by its proprietary technology infrastructure. The company offers courses in large-class format, which amplifies the benefits of online education and allows it to rapidly expand its student base. It operates solely in the PRC and all assets are located in the PRC. The learning services that the company offers include Traditional Learning Services, Non-Academic Tutoring Services, and College Student and Adult Education Services. It derives maximum revenue from Learning Services and also from Educational content & digitalized learning products.
Lyell Immunopharma Inc s a late-stage clinical cell therapy company advancing a pipeline of proprietary next-generation autologous chimeric antigen receptor (CAR) T-cell product candidates for patients with hematologic malignancies and solid tumors. The Company's product candidate, rondecabtagene autoleucel (ronde-cel, also known as LYL314), is an autologous dual-targeting CD19/CD20 CAR T-cell therapy in development for large B-cell lymphoma (LBCL). The Company has recently acquired exclusive rights outside of mainland China, Hong Kong, Macau and Taiwan, to a novel guanylyl cyclase C (GCC)-targeted CAR T-cell product candidate in early clinical development for refractory metastatic colorectal cancer (mCRC) and other GCC-expressing cancers.